TRCT
APRE icon

Tower Research Capital (TRC)’s Aprea Therapeutics APRE Stock Holding History

Tower Research Capital (TRC)’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.91K Sell
5,127
-2,700
-34% -$2.12K ﹤0.01% 4251
2025
Q4 		$6.68K Buy
7,827
+7,259
+1,278% +$8.91K ﹤0.01% 4056
2025
Q3 		$838 Sell
568
-2,395
-81% -$3.94K ﹤0.01% 4927
2025
Q2 		$5.01K Sell
2,963
-363
-11% -$619 ﹤0.01% 4237
2025
Q1 		$6.79K Buy
3,326
+1,848
+125% +$5.79K ﹤0.01% 4013
2024
Q4 		$4.86K Buy
1,478
+163
+12% +$545 ﹤0.01% 4385
2024
Q3 		$3.62K Sell
1,315
-1,415
-52% -$4.99K ﹤0.01% 4811
2024
Q2 		$11.1K Buy
2,730
+1,604
+142% +$8.27K ﹤0.01% 4103
2024
Q1 		$7.53K Buy
1,126
+578
+105% +$3.59K ﹤0.01% 4184
2023
Q4 		$2.58K Sell
548
-1,199
-69% -$4.91K ﹤0.01% 5193
2023
Q3 		$7.28K Sell
1,747
-1,578
-47% -$5.75K ﹤0.01% 4484
2023
Q2 		$10.5K Buy
3,325
+1,848
+125% +$6.89K ﹤0.01% 4116
2023
Q1 		$7K Sell
1,477
-902
-38% -$6.66K ﹤0.01% 4713
2022
Q4 		$15K Buy
2,379
+1,263
+113% +$13.3K ﹤0.01% 3398
2022
Q3 		$15K Sell
1,116
-1,252
-53% -$22.2K ﹤0.01% 4151
2022
Q2 		$36K Buy
2,368
+696
+42% +$16K ﹤0.01% 3173
2022
Q1 		$62K Buy
1,672
+571
+52% +$23.4K ﹤0.01% 2556
2021
Q4 		$64K Buy
1,101
+921
+512% +$81.4K ﹤0.01% 2563
2021
Q3 		$18K Sell
180
-144
-44% -$13.1K ﹤0.01% 3800
2021
Q2 		$31K Sell
324
-179
-36% -$16.5K ﹤0.01% 3443
2021
Q1 		$51K Buy
503
+320
+175% +$37.3K ﹤0.01% 3102
2020
Q4 		$18K Sell
183
-250
-58% -$119K ﹤0.01% 3924
2020
Q3 		$208K Buy
433
+360
+493% +$201K ﹤0.01% 2540
2020
Q2 		$56K Buy
+73
New +$47.9K ﹤0.01% 2958

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Tower Research Capital (TRC)'s APRE Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Aprea Therapeutics (APRE) stake by 34% in Q1 2026, selling an estimated $2.12K and leaving 5,127 shares worth $3.91K. The position accounts for ﹤0.01% of the portfolio, ranked #4251.

Tower Research Capital (TRC) first reported a position in APRE in Q2 2020 and has held it in 24 quarters since. The position peaked at $208K in Q3 2020. 22 funds tracked by Wall St. Rank hold APRE as of Q1 2026.

  • Tower Research Capital (TRC) held 5,127 shares of Aprea Therapeutics worth $3.91K as of Q1 2026.
  • Tower Research Capital (TRC) sold 2,700 Aprea Therapeutics shares in Q1 2026, an estimated $2.12K.
  • Aprea Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4251 holding.
  • Tower Research Capital (TRC) first reported a position in Aprea Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • Tower Research Capital (TRC)'s Aprea Therapeutics position peaked at $208K in Q3 2020.
  • 22 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.